These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16179101)

  • 1. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
    Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
    Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
    Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
    Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
    Ohyanagi F; Horiike A; Okano Y; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):503-8. PubMed ID: 17483949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
    Agelaki S; Syrigos K; Christophylakis C; Boukovinas J; Varthalitis J; Pavlakou G; Athanasiadis A; Kouroussis C; Vardakis N; Maltezakis G; Milaki G; Georgoulias V;
    Oncology; 2004; 66(3):192-6. PubMed ID: 15218309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
    Masters GA; Declerck L; Blanke C; Sandler A; DeVore R; Miller K; Johnson D;
    J Clin Oncol; 2003 Apr; 21(8):1550-5. PubMed ID: 12697880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
    Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
    Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
    Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
    J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
    Hoang T; Kim K; Jaslowski A; Koch P; Beatty P; McGovern J; Quisumbing M; Shapiro G; Witte R; Schiller JH
    Lung Cancer; 2003 Oct; 42(1):97-102. PubMed ID: 14512193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
    Pallis AG; Agelidou A; Agelaki S; Varthalitis I; Pavlakou G; Gerogianni A; Papakotoulas P; Rapti A; Chandrinos V; Christophyllakis C; Georgoulias V
    Lung Cancer; 2009 Aug; 65(2):187-91. PubMed ID: 19100647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
    Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
    Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
    Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study.
    Ichiki M; Gohara R; Rikimaru T; Kitajima T; Fujiki R; Shimada A; Aizawa H
    Chemotherapy; 2003 Jul; 49(4):200-5. PubMed ID: 12886056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Hartmann C; Weinel P; Schmid H; Grigull L; Sander A; Linderkamp C; Welte K; Reinhardt D
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):344-9. PubMed ID: 21572345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
    Rocha Lima CM; Eckardt JR; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Bahadori HR; Green MR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PubMed ID: 10585008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
    Lipton A; Campbell-Baird C; Witters L; Harvey H; Ali S
    J Clin Gastroenterol; 2010 Apr; 44(4):286-8. PubMed ID: 20216081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
    Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
    Saif MW; Sellers S; Li M; Wang W; Cusimano L; Wang H; Zhang R
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):871-82. PubMed ID: 17345085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.